Epidemiology of pertussis in two Ibero-American countries with different vaccination policies: lessons derived from different surveillance systems

Table 1 Incidence of notified pertussis, vaccines, vaccination schedules and coverage in Spain and Dominican Republic, 2005–2014

Country	Global Incidence per 100,000 inhab.^a	Incidence per 100,000 inhab. ≤1 year-old	Vaccine	Manufacturer	Global coverage^b (%)	Vaccination Schedule^c (type vaccine)
Spain (Iberian country)	3.4 (0.5–8,4)	813.3	Infanrix Hexa® Infanrix VPI Hib® Pentavac®	GlaxoSmithKline Biologicals, S.A. Sanofi Pasteur MSD, S.A.	96.5	Primary: 2, 4, 6 mo. Booster: 15–18 mo and 4–6 yr (DTaP)
DR (Caribbean country)	12.1 (1.0–37.0)	132.0	Quinvaxem® Tritanrix® HB DTCHepB.Hib®	GlaxoSmithKline Biologicals, S.A.	82.2	Primary: 2, 4, 6 mo. Booster: 18 mo and 4 yr (DTwP)

^aCare should be taken when comparing incidences between countries because of the different surveillance and diagnostic methods used
^bcoverage in children aged 2, 4 and 6 months (primary series coverage in children)
^ctwo booster doses are given in DR and Spain at the age of 18 months and 4 years-old, and between 4–6 years

ISSN: 1471-2458